Mastrapasqua Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Mastrapasqua Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$206K	Buy	2,824 +335	+13%	+$26.8K	0.02%	147
2023 Q2	$207K	Buy	+2,489	New	+$208K	0.02%	147

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Mastrapasqua Asset Management's XBI Position: Q3 2023 in Review

Mastrapasqua Asset Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 13% in Q3 2023, buying an estimated $26.8K and bringing the position to 2,824 shares worth $206K. The position accounts for 0.02% of the portfolio, ranked #147.

Mastrapasqua Asset Management first reported a position in XBI in Q2 2023 and has held it in 2 quarters since. The position peaked at $207K in Q2 2023. 679 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Mastrapasqua Asset Management held 2,824 shares of State Street SPDR S&P Biotech ETF worth $206K as of Q3 2023.
Mastrapasqua Asset Management bought 335 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $26.8K.
State Street SPDR S&P Biotech ETF made up 0.02% of Mastrapasqua Asset Management's portfolio in Q3 2023, its #147 holding.
Mastrapasqua Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and has held it in 2 quarters since.
Mastrapasqua Asset Management's State Street SPDR S&P Biotech ETF position peaked at $207K in Q2 2023.
679 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Mastrapasqua Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.